Aquestive Therapeutics, Inc. Accounts Payable and Accrued Liabilities, Current
Aquestive Therapeutics, Inc. (AQST) had Accounts Payable and Accrued Liabilities, Current of $6.37 million as of 2021-03-31, per its 10-Q filed 2021-05-04.
Discontinued › Balance Sheet › Liabilities
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent · last filed 2021-05-04
- 2021-03-31: Accounts Payable and Accrued Liabilities, Current $6.37M.
- 2020-12-31: Accounts Payable and Accrued Liabilities, Current $8.57M.
- 2020-09-30: Accounts Payable and Accrued Liabilities, Current $15.24M.
- 2020-06-30: Accounts Payable and Accrued Liabilities, Current $13.39M.
| Period end | Accounts Payable and Accrued Liabilities, Current |
|---|---|
| 2021-03-31 | $6.37M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $8.57M 10-Q · filed 2021-05-04 |
| 2020-09-30 | $15.24M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $13.39M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $14.09M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $17.75M 10-Q · filed 2020-11-04 |
| 2019-09-30 | $19.22M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $23.48M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $22.09M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $27.63M 10-Q · filed 2019-11-05 |
| 2018-09-30 | $17.80M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $21.14M 10-Q · filed 2018-09-04 |
| 2017-12-31 | $14.00M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |